Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + tegafur + uracil
- Development stage
- Unknown
- Lead developer
- Taiho Pharmaceutical
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
Gemcitabine + tegafur + uracil is a combination chemotherapy regimen used primarily in the treatment of advanced cancers such as non-small cell lung cancer (NSCLC) and pancreatic cancer. Gemcitabine is a nucleoside analog that inhibits DNA synthesis by incorporating into DNA and causing chain termination, leading to apoptosis of rapidly dividing tumor cells. Tegafur is a prodrug that is metabolized to 5-fluorouracil (5-FU), which acts as an antimetabolite inhibiting thymidylate synthase and interfering with both DNA synthesis and RNA function. Uracil enhances the efficacy of tegafur by inhibiting dihydropyrimidine dehydrogenase, thereby increasing systemic exposure to 5-FU. This combination has demonstrated activity in patients who have failed previous platinum-based chemotherapy regimens for NSCLC and has also been studied in advanced pancreatic carcinoma[1][3][6][8].
- Brand names
- Uftoral
- Other names
- gemcitabine plus UFURgemcitabine plus UFTgemcitabine combined with uracil-tegafur
02
Targets
DNATS (Thymidylate synthase)DPYD (Dihydropyrimidine dehydrogenase)
Beyond the preview
Go deeper on gemcitabine + tegafur + uracil.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + tegafur + uracil.